U.S. markets closed

Chimerix, Inc. (CMRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8100+0.1200 (+3.25%)
At close: 1:00PM EST

Chimerix, Inc.

2505 Meridian Parkway
Suite 100
Durham, NC 27713
United States
919 806 1074

Full Time Employees43

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael A. ShermanCEO, Pres & Director869.4kN/A1966
Mr. Michael T. Andriole M.B.A.Chief Bus. Officer, Sec. & CFO539.79kN/A1973
Dr. Michael A. AlrutzSr. VP, Gen. Counsel & Corp. Sec.619.5kN/A1970
Mr. David JakemanExec. Director of Fin. & Accounting and Principal Accounting OfficerN/AN/A1977
Dr. Roy W. Ware Ph.D., MBAChief Manufacturing & Technology OfficerN/AN/AN/A
Dr. Randall Lanier Ph.D.Chief Science OfficerN/AN/AN/A
Ms. Michelle LaSpalutoVP of Strategic Planning & Investor RelationsN/AN/AN/A
Dr. Allen S. Melemed M.B.A., M.D.Chief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Chimerix, Inc., a development-stage biopharmaceutical company, focuses on accelerating the advancement of various medicines that impact in the lives of patients living with cancer and other serious diseases. Its clinical stage development programs include dociparstat sodium (DSTAT), a potential first-in-class glycosaminoglycan compound derived from porcine heparin that has low anticoagulant activity but retains the ability to inhibit activities of key proteins implicated in the retention and viability of acute myeloid leukemia blasts and leukemic stem cells in the bone marrow during chemotherapy; and brincidofovir (BCV), an antiviral drug candidate in development as a medical countermeasure for smallpox. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications; and University of Michigan to research, develop, manufacture, and commercialize various products. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

Corporate Governance

Chimerix, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 7. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.